1.Date of occurrence of the event:2016/06/07
2.Company name: OBI Pharma, Inc.
3.Relationship to the Company (please enter ”head office” or”subsidiaries”): The Company head office
4.Reciprocal shareholding ratios: N/A
5.Cause of occurrence: To correct the company’s Investor Conference presentation content on June 5 2016
6.Information items/ statements to be corrected: The company’s Investor Conference presentation on June 5 2016
7.Amounts/ contents/ number of page to be corrected: Summary and Conclusions: Treatment response appears to be independent of tumor biologic subtype and Globo H expression levels. /Page 21.
8.Amounts/ contents/ number of page after correction: Summary and Conclusions: Treatment response appears to be independent of tumor biologic subtype and Globo H expression levels. /Page 21.
9.Countermeasures: To avoid the misunderstandings, the English word ‘Independent’ on Page 21 of Original presentation should be translated as ‘irrelevant’.
Some media and reports seriously misunderstand the company’s study conclusion of the therapeutic breast cancer vaccine OBI-822, referring to the response to treatment with the patient completely unrelated to the performance of Globo H inside the body, which is totally in the opposite side. OBI-822 is a vaccine designed based on the antigen identification of Globo-H. This research has been confirmed that, for the treatment response to OBI-822, there is no significant correlation with/without the performance of the Globo-H; but after the treatment with OBI-822, the antibodies of Globo-H will be produced, and with the antibodies, there will be therapeutic effect; and the higher the antibody concentration, the better the effect is.
10.Any other matters that need to be specified: None.